CRISPR Therapeutics
CRSP
CRSP
470 hedge funds and large institutions have $3.5B invested in CRISPR Therapeutics in 2023 Q4 according to their latest regulatory filings, with 120 funds opening new positions, 133 increasing their positions, 124 reducing their positions, and 45 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
1.38% more ownership
Funds ownership: 69.06% → 70.44% (+1.4%)
7% more repeat investments, than reductions
Existing positions increased: 133 | Existing positions reduced: 124
1% more call options, than puts
Call options by funds: $304M | Put options by funds: $301M
Holders
470
Holding in Top 10
4
Calls
$304M
Puts
$301M
Top Buyers
| 1 | +$85.9M | |
| 2 | +$45.5M | |
| 3 | +$29.7M | |
| 4 |
Jane Street
New York
|
+$21.9M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$15.8M |
Top Sellers
| 1 | -$27M | |
| 2 | -$15.7M | |
| 3 | -$14.2M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.6M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$13.5M |